Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12089122 | 0.89 | SMN1; SMN2 (0.50) | MAPTALDH1A1LMNASMN1; SMN2NPC1 | |
| SCHEMBL7210303 | 0.87 | MAPT (0.52) | MAPTALDH1A1LMNASMN1; SMN2NPC1 | |
| SCHEMBL7210307 | 0.84 | MAPT (0.49) | MAPTALDH1A1LMNASMN1; SMN2NPC1 | |
| SCHEMBL7210312 | 0.84 | MAPT (0.49) | MAPTALDH1A1LMNASMN1; SMN2NPC1 | |
| SCHEMBL14714240 | 0.84 | KMT2A (0.42) | MAPTALDH1A1LMNASMN1; SMN2NPC1 | |
| SCHEMBL27736701 | 0.82 | CYP1A2 (0.59) | MAPTALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL19193928 | 0.82 | TSHR (0.50) | MAPTALDH1A1LMNASMN1; SMN2NPC1 | |
| SCHEMBL14099278 | 0.82 | ALDH1A1 (0.55) | MAPTALDH1A1LMNASMN1; SMN2NPC1 | |
| SCHEMBL7109468 | 0.81 | ALDH1A1 (0.54) | MAPTALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL27732126 | 0.81 | KDM4E (0.40) | MAPTALDH1A1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073969-B2 | Compounds and methods for purifying peptides produced by solid phase peptide synthesis | Centre National de la Recherche Scientifique—CNRS (FR) | 2015-07-07 | — | — | US | disclosed |
| US-20120226019-A1 | COMPOUNDS AND METHODS FOR PURIFYING PEPTIDES PRODUCED BY SOLID PHASE PEPTIDE SYNTHESIS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS (FR) | 2012-09-06 | — | — | US | disclosed |
| EP-1869041-A1 | TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060234997-A1 | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2006-10-19 | — | — | US | disclosed |
| WO-2006103559-A1 | TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060234997-A1 | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | PTGDR, GRIN2A, PTGDR2 | MAPT 2060/4885ALDH1A1 826/4885LMNA 2787/4885 |
| US-20120226019-A1 | COMPOUNDS AND METHODS FOR PURIFYING PEPTIDES PRODUCED BY SOLID PHASE PEPTIDE SYNTHESIS | VIP, QPCT, PTMS | MAPT 3220/4885ALDH1A1 4667/4885LMNA 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.